Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials

Joe Y. Chang, Suresh Senan, Marinus A. Paul, Reza J. Mehran, Alexander V. Louie, Peter Balter, Harry J. M. Groen, Stephen E. McRae, Joachim Widder, Lei Feng, Ben E. E. M. van den Borne, Mark F. Munsell, Coen Hurkmans, Donald A. Berry, Erik van Werkhoven, John J. Kresl, Anne-Marie Dingemans, Omar Dawood, Cornelis J. A. Haasbeek, Larry S. CarpenterKatrien De Jaeger, Ritsuko Komaki, Ben J. Slotman, Egbert F. Smit, Jack A. Roth

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)630-637
JournalLancet oncology
Volume16
Issue number6
DOIs
Publication statusPublished - Jun 2015

Cite this

Chang, J. Y., Senan, S., Paul, M. A., Mehran, R. J., Louie, A. V., Balter, P., Groen, H. J. M., McRae, S. E., Widder, J., Feng, L., van den Borne, B. E. E. M., Munsell, M. F., Hurkmans, C., Berry, D. A., van Werkhoven, E., Kresl, J. J., Dingemans, A-M., Dawood, O., Haasbeek, C. J. A., ... Roth, J. A. (2015). Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet oncology, 16(6), 630-637. https://doi.org/10.1016/S1470-2045(15)70168-3